NOVEL MUCOSAL VACCINE APPROACHES FOR PNEUMONIA.

支持在故意释放或应对自然发生的传染病(包括新出现的传染病)爆发后使用的候选产品的高级开发。该合同可能支持单独疫苗成分的配方和制造，以及稳定性测试、动物模型的非临床免疫原性和有效性测试、IND启用GLP毒理学、提交IND以及临床安全性和有效性评估。

To support the advanced development of candidate products for use following the intentional release of or in response to naturally occurring outbreaks of infectious diseases, including emerging infectious diseases. This contract may support formulation and manufacture of the individual vaccine components, as well as stability testing, nonclinical immunogenicity and efficacy testing in animal models, IND enabling GLP toxicology, submission of an IND and clinical safety and efficacy evaluation.